NCT00100932: Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy |
|
|
| Completed | 2 | 106 | US | E7389 28 Day Cycle, E7389 21 Day Cycle | Eisai Inc. | Non-Small-Cell Lung Carcinoma | 06/08 | | | |
NCT00400829: E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 66 | US | eribulin mesylate, B1939, E7389, ER-086526, halichrondrin B analog | National Cancer Institute (NCI) | Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | 01/11 | 01/11 | | |
